DOCSLIB.ORG

FDA-Approved Drug Library Mini (96-Well)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FDA-Approved Drug Library Mini (96-Well) • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com FDA-Approved Drug Library Mini (96-well) Product Details: Catalog Number: CS-L022M Formulation: A collection of 1946 marketed drugs supplied as pre-dissolved Solutions Container: 96-well Plate With Peelable Foil Seal Storage: -80°C Shipping: Blue ice Packaging: Inert gas Plate layout: CS-L022M-1 1 2 3 4 5 6 7 8 9 10 11 12 Hydrocortison Fusidic acid Oxiconazole Ethoxzolamid Oseltamivir a Empty e buteprate (sodium salt) Dithranol nitrate Resveratrol e Ilaprazole Morinidazole acid Mozavaptan Empty Amfenac Hexaminolev Cefozopran Miglustat Buspirone b Empty Bromisoval Tetrahydrobio (Sodium ulinate (hydrochlorid (hydrochlorid (hydrochlorid Bleomycin Terpin Apronal Empty pterin Hydrate) (hydrochlorid e) e) e) (sulfate) (hydrate) Nefazodone Puromycin Prasugrel Morinidazole c Empty Alarelin Faropenem (hydrochlorid (dihydrochlori (hydrochlorid Tinoridine Tolazamide (R Rolapitant Revefenacin Empty (Acetate) sodium e) de) e) hydrochloride enantiomer) Benzamil 2- Cyclobenzapr Yohimbine d Empty (hydrochlorid Ethoxybenza Ivermectin ine Emamectin Ipriflavone Terfenadine Iopromide (Hydrochlorid Capsaicin Empty e) mide (hydrochlorid (Benzoate) e) Dihydroergota Fexofenadine e Empty Raltitrexed mine Vitamin K1 Levetiracetam Ornidazole Artemether Troxipide Lesinurad (hydrochlorid Treprostinil Empty (mesylate) (Levo-) (sodium) e) (sodium) Tripelennami Methylbenact f Empty Nadifloxacin Guacetisal Benactyzine Nitroxoline ne Benzyl Levodropropi Piperacillin Mafenide yzium Empty hydrochloride (hydrochlorid benzoate zine (sodium) (Acetate) Bromide Medroxyprog Triflupromazi Dinoprost 6- Trimethobenz g Empty esterone Sorafenib ne Cefamandole Riboflavin Ibuprofen (tromethamin Ketoprofen Mercaptopuri amide Empty acetate (hydrochlorid (sodium) Tetrabutyrate e salt) ne (hydrochlorid Esmolol h Empty Sodium Dimenhydrina Felbamate Benzbromaro 5-Azacytidine Etripamil (hydrochlorid Brivudine Quinidine Anidulafungin Empty gualenate te ne e) Plate layout: CS-L022M-2 1 2 3 4 5 6 7 8 9 10 11 12 Atropine Mexiletine Nicardipine Crizotinib a Empty (sulfate Danazol Triclabendazo (hydrochlorid (hydrochlorid Sildenafil (hydrochlorid Orotic acid Pravastatin Ethionamide Empty monohydrate) le e) e) (citrate) e) (sodium) Grazoprevir Paroxetine b Empty potassium Chloroxine Parecoxib Didanosine (hydrochlorid Nitisinone Aspirin Allopurinol Irsogladine Palbociclib Empty salt e) (isethionate) Dibucaine Naphazoline c Empty N/A Diphylline Pitavastatin Ingenol (hydrochlorid Lansoprazole Dienogest (hydrochlorid Avanafil Nifuratel Empty (Calcium) Mebutate e) e) Betaxolol Edoxaban L-Thyroxine d Empty Ebastine Fluticasone Mosapride Xylitol (hydrochlorid Nateglinide (tosylate Fenoldopam Octocrylene (sodium salt Empty (propionate) (citrate) e) monohydrate) (mesylate) pentahydrate) Chlorphenira Dapagliflozin Sertraline e Empty mine Vildagliptin ((2S)-1,2- Alibendol Daptomycin Emtricitabine Sorafenib (hydrochlorid Telaprevir Nepafenac Empty (maleate) propanediol, (Tosylate) e) Ramosetron Cefprozil f Empty Cidofovir Alvimopan N/A Mitiglinide Fenticonazole Azathioprine (Hydrochlorid Zidovudine Etidronic acid (monohydrate Empty (dihydrate) (calcium) (Nitrate) e) ) Rimantadine Dexmedetomi Procainamide g Empty Cilostazol Azithromycin Tamoxifen (hydrochlorid Mitotane Loxapine Carvedilol dine (hydrochlorid Sodium Empty (Citrate) e) (hydrochlorid e) nitroprusside Phenformin Umifenovir Pioglitazone Loperamide h Empty Isosorbide Ponatinib (hydrochlorid (hydrochlorid Pentostatin Canagliflozin (hydrochlorid Cortisone (hydrochlorid Embelin Empty mononitrate e) e) (hemihydrate) e) acetate e) Plate layout: CS-L022M-3 1 2 3 4 5 6 7 8 9 10 11 12 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA Tel: 732-484-9848 Fax: 888-484-5008 Email: [email protected] • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com Fenoprofen a Empty Febuxostat (Calcium Guanabenz Cefditoren Sumatriptan Glibenclamid Tropicamide Carbidopa Nevirapine Meropenem Empty hydrate) (Acetate) (Pivoxil) (succinate) e (trihydrate) Carbamazepi Vilanterol b Empty Mirabegron Tioconazole ne Clofibrate (trifenatate) Efinaconazole Iloperidone Simvastatin Irbesartan Acitretin Empty Migalastat Levocarnitine c Empty N/A (hydrochlorid Orlistat Chlorambucil Sodium D-Mannitol Hydroquinidin propionate Chlorquinaldo Mitoxantrone Empty e) diatrizoate e (hydrochlorid l Nortriptyline Belotecan Garenoxacin d Empty (hydrochlorid Aripiprazole (hydrochlorid (Mesylate Sulfacarbami Cinoxacin Glecaprevir Dydrogestero Ticarcillin Ferulic acid Empty e) e) hydrate) de ne (disodium) (sodium) Taurodeoxyc Glycerol 9- e Empty Alprenolol Clioquinol Enasidenib holic acid Zanubrutinib Deoxycholic phenylbutyrat Cortisone Ioversol Aminoacridin Empty (sodium acid e e Asenapine Niraparib f Empty (hydrochlorid Bepridil Salmeterol Mezlocillin Eslicarbazepi (hydrochlorid Vorapaxar Diflorasone Sucrose L-Thyroxine Empty e) hydrochloride (sodium) ne acetate e) Benfluorex g Empty Fludarabine Auranofin Pexidartinib Ethosuximide Riluzole Vorinostat (hydrochlorid Flucloxacillin Linezolid Vinorelbine Empty hydrochloride e) sodium (ditartrate) Cinacalcet Eperisone Alprenolol h Empty (hydrochlorid Piperonyl (hydrochlorid Daphnetin Estrone Edoxaban N/A (hydrochlorid Estradiol Temoporfin Empty e) butoxide e) e) Plate layout: CS-L022M-4 1 2 3 4 5 6 7 8 9 10 11 12 Rotigotine Ropivacaine a Empty Acetazolamid Gemifloxacin Alpha- Nelarabine (Hydrochlorid (hydrochlorid Ertugliflozin Aspartame Lofexidine Pralatrexate Empty e (mesylate) Estradiol e) e) Atomoxetine Irinotecan b Empty Gadoteridol (hydrochlorid Lenalidomide (hydrochlorid Hydrocortison Urapidil Tiotropium L-Lactic acid 5-Fluorouracil N/A Empty e) e trihydrate) e cypionate (Bromide) Dobutamine Hydroxyzine Cevimeline c Empty Arterolane (hydrochlorid Toloxatone Pimavanserin (dihydrochlori Helicid Oxybutynin (hydrochlorid Rabeprazole Moxalactam Empty e) tartrate de) e) (sodium) (sodium salt) Guanidine Xylometazolin d Empty Ixazomib Pinaverium Gallamine (hydrochlorid Methyldopa Reboxetine e Bepotastine Altretamine Methylcobala Empty bromide Triethiodide e) (hydrate) (mesylate) (hydrochlorid (besilate) min Phenoxybenz Bendamustin Ethambutol e Empty amine Lomitapide Bimatoprost Loteprednol e Epinastine Tiopronin Busulfan (dihydrochlori Menaquinone Empty (hydrochlorid Etabonate (hydrochlorid de) -4 Butenafine Doxepin Sodium 4- Clomipramine f Empty (Hydrochlorid (Hydrochlorid phenylbutyrat Oxcarbazepin Methylprednis (hydrochlorid Mesna Lacidipine Riluzole Oxytetracyclin Empty e) e) e e olone e) e Amantadine Tetrahydrozol g Empty Clotrimazole Edrophonium Binimetinib Bicalutamide Desonide (hydrochlorid Racecadotril Tolvaptan ine Nifedipine Empty (chloride) e) (hydrochlorid Hydroxyfasud Sarpogrelate Vilazodone h Empty Sulfameter Deflazacort Glycopyrrolat il (hydrochlorid Carteolol (Hydrochlorid Tranilast Saquinavir Nintedanib Empty e (hydrochlorid e) hydrochloride e) esylate Plate layout: CS-L022M-5 1 2 3 4 5 6 7 8 9 10 11 12 Amitriptyline Ropivacaine Propafenone Eflornithine a Empty (hydrochlorid (hydrochlorid Acetohexami 6- Amifampridin (hydrochlorid Econazole (hydrochlorid Elvitegravir Rifapentine Empty e) e de Thioguanine e e) (nitrate) e hydrate) Homatropine Acetophenazi b Empty Lodenafil Luliconazole (methylbromi Gadodiamide Prednisone Fruquintinib Prednisone Afloqualone Alfuzosin ne Empty de) (hydrate) acetate (dimaleate) Amiloride Aliskiren c Empty N/A Prucalopride (S)-Timolol (hydrochlorid Bisacodyl Pyridostigmin Lamivudine (hemifumarat Bambuterol Clofazimine Empty (succinate) (Maleate) e) e (bromide) e) hydrochloride Diphenidol Demeclocycli d Empty (hydrochlorid Clarithromyci Ritonavir Cefoperazon Dabigatran Tezacaftor Fludarabine Sonidegib Silibinin ne Empty e) n e etexilate (phosphate) (hydrochlorid Olopatadine e Empty Oxybutynin Zonisamide (hydrochlorid Meprednison Brinzolamide Mupirocin Naftopidil Cisatracurium Gabexate Nilvadipine Empty (chloride) e) e (besylate) (mesylate) Pramipexole f Empty Duvelisib Piracetam Acetylcystein Prucalopride (dihydrochlori Clevudine Nimorazole Agomelatine Salicylic acid Pyridoxal Empty e de) phosphate Sodium 4- g Empty aminosalicylat Ramipril Glimepiride Etomidate Guaifenesin Salbutamol Tinidazole Clobetasol Adefovir Tenoxicam Empty e (dihydrate) (hemisulfate) propionate dipivoxil Dyclonine Tirofiban Detomidine Roxatidine Adiphenine Pemetrexed h Empty (hydrochlorid (hydrochlorid Betaxolol Letrozole (hydrochlorid (Acetate Loratadine (hydrochlorid (disodium Dipyridamole Empty e) e e) Hydrochloride e) hemipenta Plate layout: CS-L022M-6 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA Tel: 732-484-9848 Fax: 888-484-5008 Email: [email protected] • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com 1 2 3 4 5 6 7 8 9 10 11 12 L-5- Quinapril a Empty Hydroxytrypto Bendazol (hydrochlorid Succinylsulfat Ambroxol Sulfamethizol Secnidazole Prednisolone Ethynodiol Iproniazid Empty phan e) hiazole e acetate diacetate (phosphate) Pramocaine b Empty Primidone Pheniramine N/A Dropropizine Nicergoline (hydrochlorid Etofylline Oxaprozin Piribedil Salicylanilide Empty (Maleate) e) Atorvastatin c Empty Indinavir Valbenazine N/A Sulfachloropy Nonivamide Acefylline Nikethamide (hemicalcium Dicoumarol Gastrodin Empty (sulfate) ridazine salt) Tenofovir Ribociclib Argatroban Citalopram d Empty alafenamide Regorafenib Pimecrolimus Osalmid Lodoxamide succinate Goserelin (monohydrate Dehydrocholi (hydrobromid Empty fumarate hydrate (acetate) ) c acid e) Labetalol Tolperisone e Empty
Load more

Recommended publications
  • Neena Valecha1, Deepali Savargaonkar1, Bina Srivastava1, B
    Valecha et al. Malar J (2016) 15:42 DOI 10.1186/s12936-016-1084-1 Malaria Journal RESEARCH Open Access Comparison of the safety and efficacy of fixed‑dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open‑label study Neena Valecha1, Deepali Savargaonkar1, Bina Srivastava1, B. H. Krishnamoorthy Rao2, Santanu K. Tripathi3, Nithya Gogtay4, Sanjay Kumar Kochar5, Nalli Babu Vijaya Kumar6, Girish Chandra Rajadhyaksha7, Jitendra D. Lakhani8, Bhagirath B. Solanki9, Rajinder K. Jalali10, Sudershan Arora10, Arjun Roy10, Nilanjan Saha10, Sunil S. Iyer10, Pradeep Sharma10 and Anupkumar R. Anvikar1* Abstract Background: Chloroquine has been the treatment of choice for acute vivax malaria for more than 60 years. Malaria caused by Plasmodium vivax has recently shown resistance to chloroquine in some places. This study compared the efficacy and safety of fixed dose combination (FDC) of arterolane maleate and piperaquine phosphate (PQP) with chloroquine in the treatment of uncomplicated vivax malaria. Methods: Patients aged 13–65 years with confirmed mono-infection of P. vivax along with fever or fever in the previ- ous 48 h were included. The 317 eligible patients were randomly assigned to receive FDC of arterolane maleate and PQP (n 159) or chloroquine (n 158) for 3 days. Primaquine was given as an anti-relapse measure on day 3 and continued= for 14 consecutive days.= Primary efficacy analysis included assessment of the proportion of aparasitaemic and afebrile patients at 72 h. Safety endpoints were analysis of adverse events, vital signs, laboratory data, and abnor- malities on electrocardiograph. Patients participated in the study for at least 42 days.
    [Show full text]
  • Review Article Efforts Made to Eliminate Drug-Resistant Malaria and Its Challenges
    Hindawi BioMed Research International Volume 2021, Article ID 5539544, 12 pages https://doi.org/10.1155/2021/5539544 Review Article Efforts Made to Eliminate Drug-Resistant Malaria and Its Challenges Wote Amelo 1,2,3 and Eyasu Makonnen 1,2 1Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Addis Ababa University, Addis Ababa, Ethiopia 2Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia 3Department of Pharmacology and Toxicology, School of Pharmacy, Jimma University, Jimma, Ethiopia Correspondence should be addressed to Wote Amelo; [email protected] Received 21 January 2021; Accepted 9 August 2021; Published 30 August 2021 Academic Editor: Jane Hanrahan Copyright © 2021 Wote Amelo and Eyasu Makonnen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Since 2000, a good deal of progress has been made in malaria control. However, there is still an unacceptably high burden of the disease and numerous challenges limiting advancement towards its elimination and ultimate eradication. Among the challenges is the antimalarial drug resistance, which has been documented for almost all antimalarial drugs in current use. As a result, the malaria research community is working on the modification of existing treatments as well as the discovery and development of new drugs to counter the resistance challenges. To this effect, many products are in the pipeline and expected to be marketed soon. In addition to drug and vaccine development, mass drug administration (MDA) is under scientific scrutiny as an important strategy for effective utilization of the developed products.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Questions in the Chemical Enzymology of MAO
    Review Questions in the Chemical Enzymology of MAO Rona R. Ramsay 1,* and Alen Albreht 2 1 Biomedical Sciences Research Complex, School of Biology, University of St Andrews, St Andrews KY16 9ST, UK 2 Laboratory for Food Chemistry, Department of Analytical Chemistry, National Institute of Chemistry, Hajdrihova 19, SI-1000 Ljubljana, Slovenia; [email protected] * Correspondence: [email protected]; Tel.: +44-(0)-1334-474740 Abstract: We have structure, a wealth of kinetic data, thousands of chemical ligands and clinical information for the effects of a range of drugs on monoamine oxidase activity in vivo. We have comparative information from various species and mutations on kinetics and effects of inhibition. Nevertheless, there are what seem like simple questions still to be answered. This article presents a brief summary of existing experimental evidence the background and poses questions that remain intriguing for chemists and biochemists researching the chemical enzymology of and drug design for monoamine oxidases (FAD-containing EC 4.1.3.4). Keywords: chemical mechanism; kinetic mechanism; oxidation; protein flexibility; cysteine modifica- tion; reversible/irreversible inhibition; molecular dynamics; simulation 1. Introduction Monoamine oxidase (E.C. 1.4.3.4) enzymes MAO A and MAO B are FAD-containing Citation: Ramsay, R.R.; Albreht, A. proteins located on the outer face of the mitochondrial inner membrane, retained there Questions in the Chemical Enzymology of MAO. Chemistry 2021, by hydrophobic interactions and a transmembrane helix. The redox co-factor (FAD) is 3, 959–978. https://doi.org/10.3390/ covalently attached to a cysteine and buried deep inside the protein [1].
    [Show full text]
  • 1. Two Components, Two Sets of Lecturers
    Conditions 1. Two components, two sets of lecturers. 2. Lectures 1-5 Prof. F. Hudecz Lectures 6-9 Dr. Gy. Domány Lectures 10-12 Dr. P. Buzder-Lantos 3. Examination: two parts determined by the lecturers and one mark. - option A: written test - option B: presentation based on literature - option C: oral examination 4. Participation at lectures > 70 % [email protected] Some Approved Peptide Pharmaceuticals and their Methods of Manufacture First generatioin Second generation New generation Oxytocin (L) Carbetocin (S) Abarelix (GnRH) (L) ACTH (1-24) & (1-39) (L,S) Terlipressin (L,S) Cetrorelix (GnRH) (L) Vasopressin (L,S) Felypressin (L,S) Ganirelix (GnRH) (L) Insulin (E,SS, R) Buserelin (L,S) Eptifibatide Glucagon (E,S,R) Deslorelin (L,S) Bivalirudin (L) Calcitonins (L,S,R) Goserelin (L) Copaxone (L) TRH (L) Histrelin (L) Techtide P-289(S) Gonadorelin (L,S) Leuprolide (L,S) Cubicin (F) Somatostatin (L,S) Nafarelin (S) Fuzeon (antiHIV (H) GHRH (1-29) & (1-44) (S) Tryptorelin (L,S) Ziconotide (pain) (S) CRF (Human & Ovine) (S) Lecirelin (S) Pramlintide (diabetes) (S) Cyclosporin (F) Lanreotide (S) Exenatide (diabetes) (S) Thymopentin (L) Octreotide (L,S) Icatibant (brady-rec) Thymosin Alpha-1 (S) Atosiban (L) Romiplostim (hormon) Secretins (Human & Porcine) (E,S) Desmopressin (L,S) Degarelix (GnRH) Parathyroid Hormone (1-34) & (1-84)(S) Lypressin (L) Mifamurtide (rák, adj.) Vasoactive Intestinal Polypeptide (S) Ornipressin Ecallantide (ödéma) Brain Natriuretic Peptide (R) Pitressin (L) Liraglutide (diabetes) Cholecystokinin (L) ACE Inhibitors (Enalapril, Lisinopril) (L) Tesamorelin Tetragastrin (L) HIV Protease Inhibitors (L) Surfaxin Pentagastrin (L) Peginesatide Eledoisin (L) Carfilzomib Linaclotide (enz.inh) L = in solution; S = on solid phase; E = extraction; F = fermentation; H = hybrid synthesis; R = recombinant; SS = semi-synthesis.
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • New Therapeutic Property of Dimebon As a Neuroprotective Agent
    Send Orders for Reprints to [email protected] Current Medicinal Chemistry, 2016, 23, 1-12 1 REVIEW ARTICLE New Therapeutic Property of Dimebon as a Neuroprotective Agent Aleksey Ustyugov1, Elena Shevtsova1, George E. Barreto2,3, Ghulam Md Ashraf 4, Sergey O. Bachurin1 and Gjumrakch Aliev1,5,6,* 1Institute of Physiologically Active Compounds, Russian Academy of Sciences, Severniy Proezd 1, Cher- nogolovka, 142432, Russia; 2Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Uni- versidad Javeriana, Bogotá D.C., Colombia; 3Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile; 4King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Ara- bia; 5GALLY International Biomedical Research Consulting LLC., 7733 Louis Pasteur Drive, #330, San An- tonio, TX, 78229, USA; 6School of Health Science and Healthcare Administration, University of Atlanta, E. Johns Crossing, #175, Johns Creek, GA, 30097, USA Abstract: Dimebon (or Latrepirdine) was initially used as an anti-histamergic drug but later new therapeutic properties were rediscovered, adding to a growing body of “old” agents with prominent neuroprotective effects. In the present manuscript, we are focusing on our latest study on Dimebon with regard to brain’s pathological processes using in vivo protei- A R T I C L E H I S T O R Y nopathy models. In the study, neurodegenerative pathology has been attributed to a group of aggregate-prone proteins: hyperphosphorylated tau, fused in sarcoma and γ-synuclein , which Received: March 13, 2016 Revised: June 08, 2016 are involved in a number of neurological disorders. We have also presented our in vitro Accepted: July 24, 2016 model based on overexpression of an aberrant mutant form of transactive response DNA DOI: 10.2174/0929867323666160804 binding 43 kDa protein in cultured SH-SY5Y neuroblastoma cells.
    [Show full text]
  • Central Valley Toxicology Drug List
    Chloroform ~F~ Lithium ~A~ Chlorpheniramine Loratadine Famotidine Acebutolol Chlorpromazine Lorazepam Fenoprofen Acetaminophen Cimetidine Loxapine Fentanyl Acetone Citalopram LSD (Lysergide) Fexofenadine 6-mono- Clomipramine acetylmorphine Flecainide ~M~ Clonazepam a-Hydroxyalprazolam Fluconazole Maprotiline Clonidine a-Hydroxytriazolam Flunitrazepam MDA Clorazepate Albuterol Fluoxetine MDMA Clozapine Alprazolam Fluphenazine Medazepam Cocaethylene Amantadine Flurazepam Meperidine Cocaine 7-Aminoflunitrazepam Fluvoxamine Mephobarbital Codeine Amiodarone Fosinopril Meprobamate Conine Amitriptyline Furosemide Mesoridazine Cotinine Amlodipine Methadone Cyanide ~G~ Amobarbital Methanol Cyclobenzaprine Gabapentin Amoxapine d-Methamphetamine Cyclosporine GHB d-Amphetamine l-Methamphetamine Glutethamide l-Amphetamine ~D~ Methapyrilene Guaifenesin Aprobarbital Demoxepam Methaqualone Atenolol Desalkylfurazepam ~H~ Methocarbamol Atropine Desipramine Halazepam Methylphenidate ~B~ Desmethyldoxepin Haloperidol Methyprylon Dextromethoraphan Heroin Metoclopramide Baclofen Diazepam Hexobarbital Metoprolol Barbital Digoxin Hydrocodone Mexiletine Benzoylecgonine Dihydrocodein Hydromorphone Midazolam Benzphetamine Dihydrokevain Hydroxychloroquine Mirtazapine Benztropine Diltiazem Hydroxyzine Morphine (Total/Free) Brodificoum Dimenhydrinate Bromazepam ~N~ Diphenhydramine ~I~ Bupivacaine Nafcillin Disopyramide Ibuprofen Buprenorphine Naloxone Doxapram Imipramine Bupropion Naltrexone Doxazosin Indomethacin Buspirone NAPA Doxepin Isoniazid Butabarbital Naproxen
    [Show full text]
  • Fully Automated Dried Blood Spot Sample Preparation Enables the Detection of Lower Molecular Mass Peptide and Non-Peptide Doping Agents by Means of LC-HRMS
    Analytical and Bioanalytical Chemistry (2020) 412:3765–3777 https://doi.org/10.1007/s00216-020-02634-4 RESEARCH PAPER Fully automated dried blood spot sample preparation enables the detection of lower molecular mass peptide and non-peptide doping agents by means of LC-HRMS Tobias Lange1 & Andreas Thomas1 & Katja Walpurgis1 & Mario Thevis1,2 Received: 10 December 2019 /Revised: 26 March 2020 /Accepted: 31 March 2020 # The Author(s) 2020 Abstract The added value of dried blood spot (DBS) samples complementing the information obtained from commonly routine doping control matrices is continuously increasing in sports drug testing. In this project, a robotic-assisted non-destructive hematocrit measurement from dried blood spots by near-infrared spectroscopy followed by a fully automated sample preparation including strong cation exchange solid-phase extraction and evaporation enabled the detection of 46 lower molecular mass (< 2 kDa) peptide and non-peptide drugs and drug candidates by means of LC-HRMS. The target analytes included, amongst others, agonists of the gonadotropin-releasing hormone receptor, the ghrelin receptor, the human growth hormone receptor, and the antidiuretic hormone receptor. Furthermore, several glycine derivatives of growth hormone–releasing peptides (GHRPs), argu- ably designed to undermine current anti-doping testing approaches, were implemented to the presented detection method. The initial testing assay was validated according to the World Anti-Doping Agency guidelines with estimated LODs between 0.5 and 20 ng/mL. As a proof of concept, authentic post-administration specimens containing GHRP-2 and GHRP-6 were successfully analyzed. Furthermore, DBS obtained from a sampling device operating with microneedles for blood collection from the upper arm were analyzed and the matrix was cross-validated for selected parameters.
    [Show full text]
  • Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm
    Kidney360 Publish Ahead of Print, published on July 23, 2020 as doi:10.34067/KID.0000922020 Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm Michael R Lattanzio(1), Matthew R Weir(2) (1) Division of Nephrology, Department of Medicine, The Chester County Hospital/University of Pennsylvania Health System (2) Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD Correspondence: Matthew R Weir University of Maryland Medical Center Division of Nephrology 22 S. Greene St. Room N3W143 Baltimore, Maryland 21201 [email protected] 1 Copyright 2020 by American Society of Nephrology. Abbreviations PA=Primary Hyperaldosteronism CVD=Cardiovascular Disease PAPY=Primary Aldosteronism Prevalence in Hypertension APA=Aldosterone-Producing Adenoma BAH=Bilateral Adrenal Hyperplasia ARR=Aldosterone Renin Ratio AF=Atrial Fibrillation OSA=Obstructive Sleep Apnea OR=Odds Ratio AHI=Apnea Hypopnea Index ABP=Ambulatory Blood Pressure AVS=Adrenal Vein Sampling CT=Computerized Tomography MRI=Magnetic Resonance Imaging SIT=Sodium Infusion Test FST=Fludrocortisone Suppression Test CCT=Captopril Challenge Test PAC=Plasma Aldosterone Concentration PRA=Plasma Renin Activity MRA=Mineralocorticoid Receptor Antagonist MR=Mineralocorticoid Receptor 2 Abstract Nearly seven decades have elapsed since the clinical and biochemical features of Primary Hyperaldosteronism (PA) were described by Conn. PA is now widely recognized as the most common form of secondary hypertension. PA has a strong correlation with cardiovascular disease and failure to recognize and/or properly diagnose this condition has profound health consequences. With proper identification and management, PA has the potential to be surgically cured in a proportion of affected individuals. The diagnostic pursuit for PA is not a simplistic endeavor, particularly since an enhanced understanding of the disease process is continually redefining the diagnostic and treatment algorithm.
    [Show full text]
  • Are Supplements Supplemented? Evaluating the Composition of Complementary and Alternative Medicines Using Mass Spectrometry and Metabolomics
    Are supplements supplemented? Evaluating the composition of complementary and alternative medicines using mass spectrometry and metabolomics By Elly Gwyn Crighton BForensics in Forensic Biology & Toxicology (First Class Honours) BSc in Molecular Biology & Biomedical Science This thesis is presented for the degree of Doctor of Philosophy Perth, Western Australia at Murdoch University 2020 Declaration I declare that: i. The thesis is my own account of my research, except where other sources are acknowledged. ii. The extent to which the work of others has been used is clearly stated in each chapter and certified by my supervisors. iii. The thesis contains as its main content, work that has not been previously submitted for a degree at any other university. i Abstract The complementary and alternative medicines (CAM) industry is worth over US$110 billion globally. Products are available to consumers with little medical advice; with many assuming that such products are ‘natural’ and therefore safe. However, with adulterated, contaminated and fraudulent products reported on overseas markets, consumers may be placing their health at risk. Previous studies into product content have reported undeclared plant materials, ingredient substitution, adulteration and contamination. However, no large-scale, independent audit of CAM has been undertaken to demonstrate these problems in Australia. This study aimed to investigate the content and quality of CAM products on the Australian market. 135 products were analysed using a combination of next-generation DNA sequencing and liquid chromatography-mass spectrometry. Nearly 50% of products tested had contamination issues, in terms of DNA, chemical composition or both. 5% of the samples contained undeclared pharmaceuticals.
    [Show full text]